Acute lymphoblastic leukemia
Conditions
Interventions
Low risk group:2 courses of high dose methotrexate or 4 courses of high dose methotrexate
Intermediate risk group:Dexamethasone 8 mg/m2 per day or prednisone 60 mg/m2 per day during remission induction
Sponsors
Shanghai Children's Medical Center
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: All of the following conditions must be met: 1. Patients aged more than 1 month to less than 18 years old; 2. Patients with acute lymphoblastic leukemia diagnosed by bone marrow morphology; 3. Patients with acute lymphoblastic leukemia.
Exclusion criteria
Exclusion criteria: It shall be excluded as long as one of the following is satisfied: 1. Patients with sIgM +; 2. Who or EGIL criteria are used to diagnose patients with acute fuzzy lineage leukemia; 3. Patients with acute lymphoblastic transformation of chronic myeloid leukemia (CML); 4. 21 patients with trisomy syndrome, or congenital or hereditary diseases with organ dysfunction; 5. Other secondary leukemia patients; 6. Patients with congenital immunodeficiency disease or metabolic disease; 7. Patients with congenital heart disease and cardiac insufficiency; 8. Patients who have used glucocorticoid for more than 14 days within one month before enrollment, or patients with ABL kinase inhibitors for more than 7 days, or with any history of chemotherapy and radiotherapy in the first three months (excluding emergency radiotherapy for relieving symptoms of airway compression).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event free survival, EFS;Overall survival, OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative recurrence rate;Treatment-related mortality;Whole transcriptome sequencing; | — |
Countries
China
Contacts
Public ContactShen Shuhong
Shanghai Children's Medical Center
Outcome results
None listed